Background: Pulmonary endarterectomy (PEA) in severe chronic thromboembolic pulmonary hypertension (CTEPH) is associated with higher risks. However, recent evidence suggests that these risks may be mitigated with the use of extracorporeal membrane oxygenation (ECMO). Methods: We performed a retrospective analysis of 401 consecutive patients undergoing PEA at the Toronto General Hospital between August 2005 and March 2020. Patients with severe CTEPH defined by pulmonary vascular resistance (PVR) >1,000 dynes.s.cm-5 at the time of diagnosis were compared to those with PVR <1,000 dynes.s.cm-5. Results: The New York Heart Association (NYHA) functional class, brain natriuretic peptide (BNP) and 6-minute walk distance were worse in patients with PVR >1,000 dynes.s.cm-5. A greater proportion of patients with PVR >1,000 dynes.s.cm-5 was treated with targeted pulmonary hypertension (PH) medical therapy (38% vs. 18%, P<0.001) and initiated on inotropic support (7% vs. 0.3%, P<0.001) before PEA. Since 2014, the ECMO utilization rate increased in patients with PVR >1,000 dynes.s.cm-5 compared to those with PVR <1,000 dynes.s.cm-5 (18% vs. 3.1%, P<0.001). The hospital mortality in patients with PVR >1,000 dynes.s.cm-5 decreased from 10.3% in 2005-2013 to 1.6% in 2014-2020 (P=0.05), while the hospital mortality in patients with PVR <1,000 dynes.s.cm-5 remained stable (1.2% in 2005-2013 vs. 2.7% in 2014-2020, P=0.4). The overall survival reached 84% at 10 years in patients with PVR >1,000 dynes.s.cm-5 compared to 78% in patients with PVR <1,000 dynes.s.cm-5 (P=0.7). Conclusions: The early and long-term results of PEA in patients with severe CTEPH are excellent despite greater postoperative risks. ECMO as a bridge to recovery after PEA can be useful in patients with severe CTEPH. 2022 Annals of Cardiothoracic Surgery. All rights reserved.
Background: Pulmonary endarterectomy (PEA) in severe chronic thromboembolic pulmonary hypertension (CTEPH) is associated with higher risks. However, recent evidence suggests that these risks may be mitigated with the use of extracorporeal membrane oxygenation (ECMO). Methods: We performed a retrospective analysis of 401 consecutive patients undergoing PEA at the Toronto General Hospital between August 2005 and March 2020. Patients with severe CTEPH defined by pulmonary vascular resistance (PVR) >1,000 dynes.s.cm-5 at the time of diagnosis were compared to those with PVR <1,000 dynes.s.cm-5. Results: The New York Heart Association (NYHA) functional class, brain natriuretic peptide (BNP) and 6-minute walk distance were worse in patients with PVR >1,000 dynes.s.cm-5. A greater proportion of patients with PVR >1,000 dynes.s.cm-5 was treated with targeted pulmonary hypertension (PH) medical therapy (38% vs. 18%, P<0.001) and initiated on inotropic support (7% vs. 0.3%, P<0.001) before PEA. Since 2014, the ECMO utilization rate increased in patients with PVR >1,000 dynes.s.cm-5 compared to those with PVR <1,000 dynes.s.cm-5 (18% vs. 3.1%, P<0.001). The hospital mortality in patients with PVR >1,000 dynes.s.cm-5 decreased from 10.3% in 2005-2013 to 1.6% in 2014-2020 (P=0.05), while the hospital mortality in patients with PVR <1,000 dynes.s.cm-5 remained stable (1.2% in 2005-2013 vs. 2.7% in 2014-2020, P=0.4). The overall survival reached 84% at 10 years in patients with PVR >1,000 dynes.s.cm-5 compared to 78% in patients with PVR <1,000 dynes.s.cm-5 (P=0.7). Conclusions: The early and long-term results of PEA in patients with severe CTEPH are excellent despite greater postoperative risks. ECMO as a bridge to recovery after PEA can be useful in patients with severe CTEPH. 2022 Annals of Cardiothoracic Surgery. All rights reserved.
Entities:
Keywords:
Pulmonary thromboendarterectomy (PTE); pulmonary emboli; pulmonary hypertension (PH); surgery
Authors: Patricia A Thistlethwaite; Aaron Kemp; Lingling Du; Michael M Madani; Stuart W Jamieson Journal: J Thorac Cardiovasc Surg Date: 2006-01-18 Impact factor: 5.209
Authors: Konrad Hoetzenecker; Stefan Schwarz; Moritz Muckenhuber; Alberto Benazzo; Florian Frommlet; Thomas Schweiger; Orsolya Bata; Peter Jaksch; Negar Ahmadi; Gabriella Muraközy; Helmut Prosch; Helmut Hager; Georg Roth; György Lang; Shahrokh Taghavi; Walter Klepetko Journal: J Thorac Cardiovasc Surg Date: 2017-12-07 Impact factor: 5.209
Authors: Peter Dorfmüller; Sven Günther; Maria-Rosa Ghigna; Vincent Thomas de Montpréville; David Boulate; Jean-François Paul; Xavier Jaïs; Benoit Decante; Gérald Simonneau; Philippe Dartevelle; Marc Humbert; Elie Fadel; Olaf Mercier Journal: Eur Respir J Date: 2014-08-19 Impact factor: 16.671
Authors: B J Levvey; H M Whitford; T J Williams; G P Westall; M Paraskeva; C Manterfield; T Miller; D McGiffin; G I Snell Journal: Am J Transplant Date: 2015-07-17 Impact factor: 8.086
Authors: Eckhard Mayer; David Jenkins; Jaroslav Lindner; Andrea D'Armini; Jaap Kloek; Bart Meyns; Lars Bo Ilkjaer; Walter Klepetko; Marion Delcroix; Irene Lang; Joanna Pepke-Zaba; Gerald Simonneau; Philippe Dartevelle Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: Maxim Hardziyenka; Maria E Campian; Herre J Reesink; Sulaiman Surie; Berto J Bouma; Maarten Groenink; Christine A Klemens; Leander Beekman; Carol A Remme; Paul Bresser; Hanno L Tan Journal: J Am Coll Cardiol Date: 2011-02-22 Impact factor: 24.094
Authors: P Dartevelle; E Fadel; S Mussot; A Chapelier; P Hervé; M de Perrot; J Cerrina; F L Ladurie; D Lehouerou; M Humbert; O Sitbon; G Simonneau Journal: Eur Respir J Date: 2004-04 Impact factor: 16.671
Authors: Patricia A Thistlethwaite; Makato Mo; Michael M Madani; Reena Deutsch; Daniel Blanchard; David P Kapelanski; Stuart W Jamieson Journal: J Thorac Cardiovasc Surg Date: 2002-12 Impact factor: 5.209
Authors: Marc de Perrot; Deepa Gopalan; David Jenkins; Irene M Lang; Elie Fadel; Marion Delcroix; Raymond Benza; Gustavo A Heresi; Manreet Kanwar; John T Granton; Micheal McInnis; Frederikus A Klok; Kim M Kerr; Joanna Pepke-Zaba; Mark Toshner; Anastasia Bykova; Andrea M D' Armini; Ivan M Robbins; Michael Madani; David McGiffin; Christoph B Wiedenroth; Sebastian Mafeld; Isabelle Opitz; Olaf Mercier; Patricia A Uber; Robert P Frantz; William R Auger Journal: J Heart Lung Transplant Date: 2021-08-03 Impact factor: 10.247